You are here

FDA Says “No” for Now to Opioid-Overdose Nasal Spray

Agency requests study data

The FDA has issued a complete response letter (CRL) regarding the new drug application (NDA) for naloxone hydrochloride 2.0 mg/0.5 mL nasal spray. Amphastar Pharmaceuticals is seeking approval of the product for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

The CRL identified several issues, including a human-factors study and a device evaluation, that need to be addressed before the NDA can be approved.

Amphastar will continue to market naloxone in prefilled syringes for intramuscular administration while it pursues the NDA for intranasal naloxone.

Naloxone hydrochloride, the N-allyl derivative of oxymorphone, is the standard of care for opioid overdose. Naloxone acts by competitively binding at opiate receptors. It binds most strongly to the mu receptor but also has antagonistic activity at kappa and sigma receptors. Naloxone has little or no agonist activity and does not cause apnea. It was first approved in 1971 to reverse opioid intoxication or overdose.

Two generic products are currently available for naloxone intramuscular injection: naloxone hydrochloride 0.4 mg (Hospira) and naloxone hydrochloride 2.0 mg (Amphastar Pharmaceuticals/International Medication Systems).

Sources: Amphastar Pharmaceuticals; February 21, 2017; and FDA Briefing Document; September 1, 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug